Reviewing Kyntra Bio (NASDAQ:KYNB) & AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares AC Immune and Kyntra Bio”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AC Immune $4.31 million 50.29 -$85.03 million ($0.50) -4.26
Kyntra Bio $4.62 million 3.02 $183.45 million $45.30 0.08

Kyntra Bio has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

51.4% of AC Immune shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AC Immune and Kyntra Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AC Immune -181.38% -105.25% -25.04%
Kyntra Bio 2,199.13% N/A -47.27%

Risk & Volatility

AC Immune has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AC Immune and Kyntra Bio, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune 1 1 2 1 2.60
Kyntra Bio 1 1 5 0 2.57

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 252.11%. Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 969.77%. Given Kyntra Bio’s higher probable upside, analysts clearly believe Kyntra Bio is more favorable than AC Immune.

Summary

Kyntra Bio beats AC Immune on 9 of the 15 factors compared between the two stocks.

About AC Immune

(Get Free Report)

AC Immune SA is a Swiss biopharmaceutical company focused on developing precision medicines and diagnostic products for neurodegenerative diseases. Its research programs address conditions including Alzheimer’s and Parkinson’s diseases, as well as other neurological disorders. The company’s pipeline includes immunotherapies and small-molecule drug candidates designed to target proteins associated with neurodegeneration. AC Immune also develops diagnostic approaches and uses proprietary technology platforms, including SupraAntigen and Morphomer, to identify and advance potential treatments.

About Kyntra Bio

(Get Free Report)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.